Cargando…

Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan

BACKGROUND: To assess persistence rates of biologic agents for the treatment of rheumatoid arthritis in Japan. METHODS: Based on Japanese claims data of 16,214 patients between 2012 and 2014, 6-, 12-, and 18-month persistence rates of different biologic agents were calculated. Determinants of persis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahlich, Jörg, Sruamsiri, Rosarin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981174/ https://www.ncbi.nlm.nih.gov/pubmed/27540283 http://dx.doi.org/10.2147/PPA.S110147

Ejemplares similares

The underrated prevalence of depression in Japanese patients with rheumatoid arthritis - evidence from a Nationwide survey in Japan
por: Sruamsiri, Rosarin, et al.
Publicado: (2017)

Co-insurance and health care utilization in Japanese patients with rheumatoid arthritis: a discontinuity regression approach
por: Mahlich, Jörg, et al.
Publicado: (2019)

Shared Decision-Making and Patient Satisfaction in Japanese Rheumatoid Arthritis Patients: A New “Preference Fit” Framework for Treatment Assessment
por: Mahlich, Jörg, et al.
Publicado: (2019)

Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database
por: Sruamsiri, Rosarin, et al.
Publicado: (2018)

Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs
por: Sruamsiri, Rosarin, et al.
Publicado: (2018)

Biologic treatment of Japanese patients with inflammatory bowel disease
por: Mahlich, Jörg, et al.
Publicado: (2018)

Hospitalization costs and length of stay of Japanese children with respiratory syncytial virus: A structural equation modeling approach
por: Sruamsiri, Rosarin, et al.
Publicado: (2018)

Treatment patterns and healthcare resource utilization in palmoplantar pustulosis patients in Japan: A claims database study
por: Miyazaki, Celine, et al.
Publicado: (2020)

Preferences Regarding Shared Decision-Making in Japanese Inflammatory Bowel Disease Patients
por: Morishige, Ryuji, et al.
Publicado: (2016)

Cultural beliefs, utility values, and health technology assessment
por: Mahlich, Jörg, et al.
Publicado: (2018)

Impact of patient characteristics and treatment procedures on hospitalization cost and length of stay in Japanese patients with influenza: A structural equation modelling approach
por: Sruamsiri, Rosarin, et al.
Publicado: (2017)

Drug Utilization of Japanese Patients Diagnosed with Schizophrenia: An Administrative Database Analysis
por: Cheung, Stephane, et al.
Publicado: (2017)

The relationship between socio-demographic factors, health status, treatment type, and employment outcome in patients with inflammatory bowel disease in Japan
por: Mahlich, J, et al.
Publicado: (2017)

Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany
por: Neubauer, Sarah, et al.
Publicado: (2014)

Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis—A Retrospective Database Study
por: Sewerin, Philipp, et al.
Publicado: (2021)

Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA
por: Chastek, Benjamin, et al.
Publicado: (2017)

Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan
por: Mahlich, Jörg, et al.
Publicado: (2015)

Productivity and deadweight losses due to relapses of schizophrenia in Japan
por: Nakamura, Yusuke, et al.
Publicado: (2017)

Quality of Reporting of Randomised Controlled Trials of Herbal Interventions in ASEAN Plus Six Countries: A Systematic Review
por: Pratoomsoot, Chayanin, et al.
Publicado: (2015)

Patient Preference for Treatment Mode of Biologics in Rheumatoid Arthritis: A 2020 Web-based Survey in Japan
por: Kishimoto, Mitsumasa, et al.
Publicado: (2021)

Estimating Prevalence and Healthcare Utilization for Treatment-Resistant Depression in Japan: A Retrospective Claims Database Study
por: Mahlich, Jörg, et al.
Publicado: (2017)

Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy
por: Degli Esposti, Luca, et al.
Publicado: (2016)

Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis
por: Huynh, Tuan Khai, et al.
Publicado: (2014)

Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis
por: Takacs, Peter, et al.
Publicado: (2019)

Treatment persistence in patients with rheumatoid arthritis and ankylosing spondylitis
por: Machado, Marina Amaral de Ávila, et al.
Publicado: (2016)

Damage progression in rheumatoid arthritis: the role of biologic agents
por: Favalli, Ennio Giulio
Publicado: (2012)

A Real-World Claims Database Study Assessing Long-Term Persistence with Golimumab Treatment in Patients with Rheumatoid Arthritis in Japan
por: Miyashiro, Masahiko, et al.
Publicado: (2023)

Effects of Biologic Agents in Patients with Rheumatoid Arthritis and Amyloidosis Treated with Hemodialysis
por: Kuroda, Takeshi, et al.
Publicado: (2016)

Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
por: Mishra, Richa, et al.
Publicado: (2009)

Research on Liver Damage Caused by the Treatment of Rheumatoid Arthritis with Novel Biological Agents or Targeted Agents
por: Zhao, Xin, et al.
Publicado: (2023)

Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis
por: Migliore, Alberto, et al.
Publicado: (2015)

Thyroid Autoimmunity and Function after Treatment with Biological Antirheumatic Agents in Rheumatoid Arthritis
por: Bliddal, Sofie, et al.
Publicado: (2017)

Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan
por: Mori, Shunsuke, et al.
Publicado: (2017)

Biologic agents for rheumatoid arthritis—negotiating the NICE technology appraisals
por: Kiely, Patrick D. W., et al.
Publicado: (2012)

Polymorphisms Involved in Response to Biological Agents Used in Rheumatoid Arthritis
por: Pallio, Giovanni, et al.
Publicado: (2020)

Biologic Agents in Rheumatoid Arthritis: An Update for Managed Care Professionals
por: Agarwal, Sandeep K.
Publicado: (2011)

Patient and Physician Preferences for Therapy Characteristics for Psoriasis: A Discrete Choice Experiment in Japan
por: Bolt, Timothy, et al.
Publicado: (2018)

Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An observational study
por: Wisłowska, Małgorzata
Publicado: (2022)

Biologic monotherapy in the treatment of rheumatoid arthritis
por: Detert, Jacqueline, et al.
Publicado: (2015)

Treatment with Biologicals in Rheumatoid Arthritis: An Overview
por: Rein, Philipp, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_792ff1hhet7kr8843btlagbv5f